[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648435":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":10,"responsibleParty":29,"collaborators":31,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":10},{"fullName":5,"class":6},"The Affiliated Hospital of Qingdao University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"High-Risk Group of Recurrence or Metastasis",null,"AI-assisted patients who have high-risk of postoperative recurrence or metastasis.",[13],"Other: No Intervention: Observational Cohort",{"label":15,"type":10,"description":16,"interventionNames":17},"Low-Risk Group of Recurrence or Metastasis","AI-assisted patients who have low-risk of postoperative recurrence or metastasis.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"No Intervention: Observational Cohort","This study is an retrospective observational study. There will be no interventions on the participants.",[9,15],[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Xiaoming Xing","CONTACT","+8653282911869","edithxing@126.com",{"type":30,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[32,35,37],{"name":33,"class":34},"Shandong Provincial Hospital","OTHER_GOV",{"name":36,"class":6},"Yantai Yuhuangding Hospital",{"name":38,"class":6},"Peking University Third Hospital","100648435","artificial-intelligence-guided-precision-treatment-of-high-grade-serous-ovarian-carcinoma-100648435",false,"NCT07721675","Artificial Intelligence-guided Precision Treatment of High-grade Serous Ovarian Carcinoma","Personalized Precision Diagnosis and Treatment of High-grade Serous Ovarian Carcinoma During the Perioperative Period Assisted by Multi-omics and Artificial Intelligence Models, and Research on the Heterogeneity of Immune Microenvironment","AI-PTHGSOC","Inclusion Criteria:\n\n* Histologically confirmed high-grade serous ovarian carcinoma using resection specimens.\n* Well-preserved surgical paraffin-embedded tumor specimens.\n* Complete clinical information and survival follow-up data.\n\nExclusion Criteria:\n\n* Received preoperative neoadjuvant treatment.\n* Poor preservation of surgical paraffin specimens.\n* Incomplete clinical information and survival follow-up data.\n* With concurrent malignancies other than high-grade serous ovarian carcinoma.","FEMALE","18 Years","80 Years",{"count":51,"type":52},1300,"ESTIMATED","OBSERVATIONAL","The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and overall survival of patients based on multimodal data such as surgical pathological images (HE images and IHC images of immune microenvironment-related markers), preoperative baseline imaging data and detailed clinical information of patients. In addition, multi-omics sequencing analysis will be used to deeply explore the heterogeneity of the tumor microenvironment, with the expectation of quantifying the postoperative recurrence risk of patients with high-grade serous ovarian cancer and providing new ideas for the precise diagnosis and treatment of patients with high-grade serous ovarian cancer.",[56],"High-grade Serous Ovarian Carcinoma (HGSOC)","NOT_YET_RECRUITING","2026-07-19",{"date":60,"type":61},"2026-07-23","ACTUAL",{"date":63,"type":52},"2026-08-01",{"date":65,"type":52},"2027-12-31",{"name":5,"class":6}]